Skip to Content



A biological treatment could replace chemotherapy in patients with aggressive breast cancer

A biological treatment could replace chemotherapy in patients with aggressive breast cancer

11 Dec 2019

A biological treatment could replace chemotherapy in patients with aggressive breast cancer

Dr. Aleix Prat (on the left) and Dr. Joaquín Gavilá, CORALLEEN trial principal investigators. Source: SOLTI


  • The SOLTI-1402 CORALLEEN study, published today in The Lancet Oncology, demonstrates that neoadjuvant treatment with ribociclib and letrozole is highly effective in patients with high-risk hormone-sensitive early breast cancer.
  • The results suggest that patients with this profile may avoid chemotherapy.
  • CORALLEEN is the first study in the world to use a test based on genomic, pathological and clinical data to select patients and evaluate their response to treatment.

December 11th, 2019. SAN ANTONIO, Texas, United States - Today the results of the phase 2 CORALLEEN clinical trial, promoted by the international academic group SOLTI, were presented. The study has shown that the combination of ribociclib (KISQALI®), an inhibitor of the CDK4/6 proteins that regulate the cell cycle, with letrozole, an endocrine therapy, has a similar efficacy, in the neoadjuvant context, than chemotherapy, which is currently the standard of care. Patients who benefited were those with early hormone-sensitive breast cancer at high risk of developing distant metastases in the next 10 years. To achieve this result, 106 patients from 21 hospitals in Spain participated in the study.

Drugs that inhibit CDK4/6 such as ribociclib, in combination with endocrine therapy, have demonstrated extraordinary efficacy in metastatic breast cancer. In this context, the use of chemotherapy is not the first option anymore and its use is restricted to those cases where the treatment fails. In contrast, in patients with early breast cancer and high risk of relapse, the role of these biological drugs is not yet defined. Dr. Aleix Prat, Head of the Medical Oncology Service at Hospital Clínic of Barcelona, president of SOLTI and co-principal investigator of CORALLEEN, comments: “The numerous studies currently under way in early disease are testing these drugs as an added complement to chemotherapy. However, none is considering using them to replace chemotherapy. Based on this, CORALLEEN was designed.”

During the plenary session of the annual San Antonio Breast Cancer Symposium in Texas, USA, with more than eight thousand attendees, Dr. Joaquín Gavilá, Clinical Chief of the Valencian Oncology Institute Foundation, member of SOLTI’s Governing Board and also co-principal investigator of the study, presented the results of CORALLEEN: “We really did not know the potential of these drugs to de-escalate neoadjuvant chemotherapy. This trial reveals for the first time that it is a field worth exploring and points to how it should be done.” These results have deserved their publication in The Lancet Oncology simultaneously to the presentation at the conference.

Importantly, in addition to answering a key clinical question, CORALLEEN is the first study in the world to use real-time genomic data to more accurately select patients with high-risk tumors. Specifically, the PAM50/Prosigna® genomic test was used to select tumors with the Luminal B profile, which represents 30% of breast cancers that express hormonal receptors. In addition, the study was the first to integrate clinical, pathological and genomic data to measure the treatment response and show that in about half of the patients the treatment with ribociclib and letrozole administered for 6 months turns tumors at a high risk of recurrence into low-risk neoplasms. Regarding this point, Dr. Prat, who leads the Translational genomics and targeted therapies in solid tumors group at IDIBAPS, where all translational analysis was performed, comments: “SOLTI is characterized by designing innovative clinical trials of high complexity and very informative. CORALLEEN is an example of innovation available to few academic groups. It is important to note that we used a genomic test to select patients and assign a treatment. In addition, we decided to implement all current molecular knowledge to measure therapeutic efficacy in a much more precise way than conventional criteria. In a few years, we believe this strategy will be integrated into daily clinical practice.”

After these promising results, SOLTI already plans an upcoming study. With this in mind, Dr. Gavilá adds: “Our data suggest that ribociclib with letrozole might be an alternative to chemotherapy for high-risk patients and, to further test this hypothesis, we have designed a second study with a much larger number of patients that we hope to start in 2020 once we get the necessary funding.”

CORALLEEN is an academic clinical trial promoted by SOLTI with funding from NOVARTIS and with the support of the Breast Cancer Research Foundation.


Related Documents


SOLTI Communication Area

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.